10X Genomics Adds David Jaffe, Recognized Leader in Genome Analysis

PLEASANTON, Calif.--(BUSINESS WIRE)--10X Genomics today announced that David Jaffe, Ph.D. has joined the company as a Fellow. Dr. Jaffe will be developing computational methods to further unlock the power of the company's Linked-Read data.

"We are very pleased to welcome David Jaffe to the team," said Serge Saxonov, CEO of 10X Genomics. "David is one of the world recognized leaders in making genomic data informative and actionable through innovative analysis methods. We are excited to leverage his expertise as we enable access to the full value of the genome through long range information."

Dr. Jaffe comes to 10X Genomics from the Broad Institute, where he was Director of Computational Research and Development in the Genome Sequencing and Analysis Program. Over his 15 years there, he developed several broadly adopted methods for genome assembly and variant analysis and was instrumental in their application to investigations ranging from the properties of sequence data itself to biology and medicine.

"Linked-Reads are a powerful new data type that will provide an entirely new dimension to genomic data. It's so compelling I wanted to be part of making that happen," said Dr. Jaffe.

ABOUT 10X GENOMICS

10X Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing short read sequencers. The Company does this through a combination of elegant microfluidics, chemistry and bioinformatics. With the GemCode Platform, researchers can now find structural variants, haplotypes, and other valuable long range information while leveraging existing sequencing workflows.

Contacts
Chempetitive Group for 10X Genomics
Kena Hudson, 510-908-0966
[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.